AMRX vs. CORT

Last updated Apr 1, 2026

Compare and contrast key facts about Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT).

Performance

AMRX vs. CORT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT). The values are adjusted to include any dividend payments, if applicable.

AMRX vs. CORT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AMRX Amneal Pharmaceuticals, Inc.	-1.35%	59.09%	30.48%	205.03%	-58.46%	4.81%	-5.19%	-64.38%	-18.74%	25.66%
CORT Corcept Therapeutics Incorporated	15.83%	-30.94%	55.14%	59.92%	2.58%	-24.31%	116.20%	-9.43%	-26.02%	148.76%

Fundamentals

EPS AMRX : $0.22 CORT : $0.88
PE Ratio AMRX : 55.89 CORT : 45.97
PEG Ratio AMRX : 1.94 CORT : 22.90
PS Ratio AMRX : 1.33 CORT : 6.52
Total Revenue (TTM) AMRX : $3.02B CORT : $741.17M
Gross Profit (TTM) AMRX : $1.11B CORT : $727.78M
EBITDA (TTM) AMRX : $226.33M CORT : $72.46M

Returns By Period

In the year-to-date period, AMRX achieves a -1.35% return, which is significantly lower than CORT's 15.83% return. Over the past 10 years, AMRX has underperformed CORT with an annualized return of -9.37%, while CORT has yielded a comparatively higher 23.92% annualized return.

AMRX

• 1D: 4.02%
• 1M: -9.99%
• YTD: -1.35%
• 6M: 24.18%
• 1Y: 48.33%
• 3Y*: 107.56%
• 5Y*: 13.50%
• 10Y*: -9.37%

CORT

• 1D: 5.75%
• 1M: 12.91%
• YTD: 15.83%
• 6M: -51.50%
• 1Y: -64.71%
• 3Y*: 23.00%
• 5Y*: 10.53%
• 10Y*: 23.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AMRX vs. CORT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMRX

AMRX Risk / Return Rank: 80
AMRX Sharpe Ratio Rank: 84
AMRX Sortino Ratio Rank: 79
AMRX Omega Ratio Rank: 76
AMRX Calmar Ratio Rank: 80
AMRX Martin Ratio Rank: 81

CORT

CORT Risk / Return Rank: 18
CORT Sharpe Ratio Rank: 8
CORT Sortino Ratio Rank: 12
CORT Omega Ratio Rank: 7
CORT Calmar Ratio Rank: 31
CORT Martin Ratio Rank: 33

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AMRX vs. CORT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AMRX	CORT	Difference
Sharpe ratio Return per unit of total volatility	1.46	-0.82	+2.28
Sortino ratio Return per unit of downside risk	2.01	-0.96	+2.97
Omega ratio Gain probability vs. loss probability	1.25	0.82	+0.43
Calmar ratio Return relative to maximum drawdown	2.27	-0.36	+2.63
Martin ratio Return relative to average drawdown	6.35	-0.58	+6.93
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AMRX vs. CORT - Sharpe Ratio Comparison

The current AMRX Sharpe Ratio is 1.46, which is higher than the CORT Sharpe Ratio of -0.82. The chart below compares the historical Sharpe Ratios of AMRX and CORT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AMRX	CORT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.46	-0.82	+2.28
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.27	0.14	+0.12
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.14	0.36	-0.50
Sharpe Ratio (All Time) Calculated using the full available price history	0.10	0.07	+0.03

Correlation

The correlation between AMRX and CORT is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AMRX vs. CORT - Dividend Comparison

Neither AMRX nor CORT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AMRX vs. CORT - Drawdown Comparison

The maximum AMRX drawdown since its inception was -97.52%, roughly equal to the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for AMRX and CORT.

Drawdown Indicators

	AMRX	CORT	Difference
Max Drawdown Largest peak-to-trough decline	-97.52%	-94.28%	-3.24%
Max Drawdown (1Y) Largest decline over 1 year	-22.12%	-65.03%	+42.91%
Max Drawdown (5Y) Largest decline over 5 years	-81.38%	-71.85%	-9.53%
Max Drawdown (10Y) Largest decline over 10 years	-96.51%	-71.85%	-24.66%
Current Drawdown Current decline from peak	-75.77%	-64.71%	-11.06%
Average Drawdown Average peak-to-trough decline	-54.10%	-53.45%	-0.65%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.90%	45.10%	-37.20%

Volatility

AMRX vs. CORT - Volatility Comparison

The current volatility for Amneal Pharmaceuticals, Inc. (AMRX) is 11.31%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 21.99%. This indicates that AMRX experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AMRX	CORT	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.31%	21.99%	-10.68%
Volatility (6M) Calculated over the trailing 6-month period	23.01%	85.27%	-62.26%
Volatility (1Y) Calculated over the trailing 1-year period	33.25%	134.82%	-101.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	51.16%	73.97%	-22.81%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	65.30%	67.09%	-1.79%

Financials

AMRX vs. CORT - Profitability Comparison

The chart below illustrates the profitability comparison between Amneal Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

AMRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Amneal Pharmaceuticals, Inc. reported a gross profit of 297.19M and revenue of 814.32M. Therefore, the gross margin over that period was 36.5%.

CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Corcept Therapeutics Incorporated reported a gross profit of 203.04M and revenue of 207.64M. Therefore, the gross margin over that period was 97.8%.

AMRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Amneal Pharmaceuticals, Inc. reported an operating income of -216.84M and revenue of 814.32M, resulting in an operating margin of -26.6%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Corcept Therapeutics Incorporated reported an operating income of 10.22M and revenue of 207.64M, resulting in an operating margin of 4.9%.

AMRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Amneal Pharmaceuticals, Inc. reported a net income of 35.08M and revenue of 814.32M, resulting in a net margin of 4.3%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Corcept Therapeutics Incorporated reported a net income of 19.36M and revenue of 207.64M, resulting in a net margin of 9.3%.